Use of il-6r/il-6 chimera in huntington's disease
CA 2419954 C · Owner: Deglon, Nicole · Inventors: Aebischer, Patrick; Deglon, Nicole; Bensadoun, Jean-Charles
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to the use of an IL-6R/IL-6 chimera a mutein, isoform, fused protein, functional derivative active fraction or circularly permutated derivative or a salt thereof, for the manufacture of a medicament for the treatment and/or prevention of Huntington's disease.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 10, 2001 and granted January 3, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 10, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 10, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.